Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02783300
Title Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Acronym Meteor 1
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | FRA | CAN

Facility Status City State Zip Country Details
GSK Investigational Site Denver Colorado 80218 United States Details
GSK Investigational Site Miami Florida 33136 United States Details
GSK Investigational Site Middletown New Jersey 07748 United States Details
GSK Investigational Site Harrison New York 10604 United States Details
GSK Investigational Site New York New York 10065 United States Details
GSK Investigational Site Nashville Tennessee 37203 United States Details
GSK Investigational Site Dallas Texas 75230 United States Details
GSK Investigational Site San Antonio Texas 78229 United States Details
GSK Investigational Site Edmonton Alberta T6G 1Z2 Canada Details
GSK Investigational Site Ottawa Ontario K1H 8L6 Canada Details
GSK Investigational Site Toronto Ontario M5G 1Z5 Canada Details
GSK Investigational Site Bordeaux Cedex 33076 France Details
GSK Investigational Site Lyon Cedex 08 69373 France Details
GSK Investigational Site Villejuif cedex 94805 France Details
GSK Investigational Site Amsterdam 1066 CX Netherlands Details
GSK Investigational Site Leiden 2333 ZA Netherlands Details
GSK Investigational Site Rotterdam 3015 GD Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field